These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 26005037)

  • 1. Beyond viral response: A prospective evaluation of a community-based, multi-disciplinary, peer-driven model of HCV treatment and support.
    Mason K; Dodd Z; Sockalingam S; Altenberg J; Meaney C; Millson P; Powis J
    Int J Drug Policy; 2015 Oct; 26(10):1007-13. PubMed ID: 26005037
    [TBL] [Abstract][Full Text] [Related]  

  • 2. "It gives me a sense of belonging": providing integrated health care and treatment to people with HCV engaged in a psycho-educational support group.
    Woolhouse S; Cooper E; Pickard A
    Int J Drug Policy; 2013 Nov; 24(6):550-7. PubMed ID: 23860471
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Factors associated with HCV antiviral treatment uptake among participants of a community-based HCV programme for marginalized patients.
    Charlebois A; Lee L; Cooper E; Mason K; Powis J
    J Viral Hepat; 2012 Dec; 19(12):836-42. PubMed ID: 23121361
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of two community-controlled peer support services for assessment and treatment of hepatitis C virus infection in opioid substitution treatment clinics: The ETHOS study, Australia.
    Treloar C; Rance J; Bath N; Everingham H; Micallef M; Day C; Hazelwood S; Grebely J; Dore GJ
    Int J Drug Policy; 2015 Oct; 26(10):992-8. PubMed ID: 25697089
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Assessment and delivery of treatment for hepatitis C virus infection in an opioid substitution treatment clinic with integrated peer-based support in Newcastle, Australia.
    Keats J; Micallef M; Grebely J; Hazelwood S; Everingham H; Shrestha N; Jones T; Bath N; Treloar C; Dore GJ; Dunlop A;
    Int J Drug Policy; 2015 Oct; 26(10):999-1006. PubMed ID: 26275578
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Optimizing assessment and treatment for hepatitis C virus infection in illicit drug users: a novel model incorporating multidisciplinary care and peer support.
    Grebely J; Knight E; Genoway KA; Viljoen M; Khara M; Elliott D; Gallagher L; Storms M; Raffa JD; DeVlaming S; Duncan F; Conway B
    Eur J Gastroenterol Hepatol; 2010 Mar; 22(3):270-7. PubMed ID: 20425880
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Integrating HCV services for drug users: a model to improve engagement and outcomes.
    Sylvestre DL; Zweben JE
    Int J Drug Policy; 2007 Oct; 18(5):406-10. PubMed ID: 17854729
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Integrating multiple programme and policy approaches to hepatitis C prevention and care for injection drug users: a comprehensive approach.
    Birkhead GS; Klein SJ; Candelas AR; O'Connell DA; Rothman JR; Feldman IS; Tsui DS; Cotroneo RA; Flanigan CA
    Int J Drug Policy; 2007 Oct; 18(5):417-25. PubMed ID: 17854731
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differences in access to care among injection drug users infected either with HIV and hepatitis C or hepatitis C alone.
    Braitstein P; Li K; Kerr T; Montaner JS; Hogg RS; Wood E
    AIDS Care; 2006 Oct; 18(7):690-3. PubMed ID: 16971276
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Positive impact of hepatitis C virus (HCV) treatment on antiretroviral treatment adherence in human immunodeficiency virus-HCV coinfected patients: one more argument for expanded access to HCV treatment for injecting drug users.
    Roux P; Fugon L; Winnock M; Salmon-Céron D; Lacombe K; Sogni P; Spire B; Dabis F; Carrieri MP;
    Addiction; 2012 Jan; 107(1):152-9. PubMed ID: 21819472
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A novel program for treating patients with trimorbidity: hepatitis C, serious mental illness, and active substance use.
    Sockalingam S; Blank D; Banga CA; Mason K; Dodd Z; Powis J
    Eur J Gastroenterol Hepatol; 2013 Dec; 25(12):1377-84. PubMed ID: 23680911
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Improving access to care for people who inject drugs: Qualitative evaluation of project ITTREAT-An integrated community hepatitis C service.
    Phillips C; Schulkind J; O'Sullivan M; Edelman N; Smith HE; Verma S; Jones CJ
    J Viral Hepat; 2020 Feb; 27(2):176-187. PubMed ID: 31566851
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Barriers associated with the treatment of hepatitis C virus infection among illicit drug users.
    Grebely J; Genoway KA; Raffa JD; Dhadwal G; Rajan T; Showler G; Kalousek K; Duncan F; Tyndall MW; Fraser C; Conway B; Fischer B
    Drug Alcohol Depend; 2008 Jan; 93(1-2):141-7. PubMed ID: 17997050
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An effectiveness study of group psychoeducation for hepatitis C patients in community clinics.
    North CS; Pollio DE; Sims OT; Jain MK; Brown GR; Downs DL; Lisker-Melman M; Hong BA
    Eur J Gastroenterol Hepatol; 2017 Jun; 29(6):679-685. PubMed ID: 28195874
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tensions in relation: How peer support is experienced and received in a hepatitis C treatment intervention.
    Bonnington O; Harris M
    Int J Drug Policy; 2017 Sep; 47():221-229. PubMed ID: 28606391
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Peer outreach point-of-care testing as a bridge to hepatitis C care for people who inject drugs in Toronto, Canada.
    Broad J; Mason K; Guyton M; Lettner B; Matelski J; Powis J
    Int J Drug Policy; 2020 Jun; 80():102755. PubMed ID: 32416538
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 'Makes you wanna do treatment': benefits of a hepatitis C specialist clinic to clients in Christchurch, New Zealand.
    Brener L; Gray R; Cama EJ; Treloar C
    Health Soc Care Community; 2013 Mar; 21(2):216-23. PubMed ID: 23199074
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Framework for community-based models for treating hepatitis C virus.
    Pourmarzi D; Hall L; Smirnov A; Hepworth J; Rahman T; FitzGerald G
    Aust Health Rev; 2020 Jun; 44(3):459-469. PubMed ID: 31671288
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hepatitis C Virus seroconversion among persons who inject drugs in relation to primary care physician visiting: The potential role of primary healthcare in a combined approach to Hepatitis C prevention.
    Artenie AA; Roy É; Zang G; Jutras-Aswad D; Bamvita JM; Puzhko S; Daniel M; Bruneau J
    Int J Drug Policy; 2015 Oct; 26(10):970-5. PubMed ID: 26005038
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Integrating services for injection drug users infected with hepatitis C virus with methadone maintenance treatment: challenges and opportunities.
    Litwin AH; Soloway I; Gourevitch MN
    Clin Infect Dis; 2005 Apr; 40 Suppl 5():S339-45. PubMed ID: 15768345
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.